On June 20, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 24-04, a favorable opinion analyzing a refund and discount program designed to alleviate the...more
7/11/2024
/ Department of Health and Human Services (HHS) ,
Drug Pricing ,
Health Insurance ,
Healthcare ,
Life Sciences ,
Manufacturers ,
OIG ,
Pharmaceutical Industry ,
Prescription Drugs ,
Refunds ,
Risk Mitigation